<SEC-DOCUMENT>0001193125-21-188845.txt : 20210611
<SEC-HEADER>0001193125-21-188845.hdr.sgml : 20210611
<ACCEPTANCE-DATETIME>20210611160133
ACCESSION NUMBER:		0001193125-21-188845
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210607
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210611
DATE AS OF CHANGE:		20210611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		211011217

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d153894d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20210607" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-06-07_to_2021-06-07">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-06-07_to_2021-06-07">0001055726</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ino-20210607.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-06-07_to_2021-06-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-07</xbrli:startDate> <xbrli:endDate>2021-06-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-06-07_to_2021-06-07">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt:datemonthdayyearen">June 7, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-06-07_to_2021-06-07">Inovio Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-06-07_to_2021-06-07">001-14888</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-06-07_to_2021-06-07">33-0969592</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-06-07_to_2021-06-07">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-06-07_to_2021-06-07">Suite 110</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-06-07_to_2021-06-07">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-06-07_to_2021-06-07">PA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-06-07_to_2021-06-07">19462</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, including zip code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-06-07_to_2021-06-07">(267)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-06-07_to_2021-06-07">440-4200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-06-07_to_2021-06-07">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-06-07_to_2021-06-07">INO</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-06-07_to_2021-06-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;7, 2021, Inovio Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) entered into an Amended and Restated Collaboration and License Agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Restated Agreement</span></span>&#8221;) with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Advaccine</span></span>&#8221;). The Restated Agreement amends and restates that certain Collaboration and License Agreement, dated as of December&#160;31, 2020, by and between the Company and Advaccine (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Original Agreement</span></span>&#8221;). Under the terms of the Original Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s <span style="white-space:nowrap">COVID-19</span> DNA vaccine candidate, <span style="white-space:nowrap">INO-4800,</span> within the territories of mainland China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;<span style="font-weight:bold"><span style="font-style:italic">Greater China</span></span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2021, the Company and Advaccine announced that they intend to jointly conduct a global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of <span style="white-space:nowrap">INO-4800.</span> The Company and Advaccine entered into the Restated Agreement in order to expand their existing collaboration to include the planned global Phase 3 trial. Under the Restated Agreement, the Company has granted to Advaccine the exclusive right to develop, manufacture and commercialize <span style="white-space:nowrap">INO-4800</span> within 33 additional countries in Asia. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Restated Agreement, the parties have agreed to use their commercially reasonable efforts to design a global Phase 3 study plan and to conduct the trial in accordance with that plan. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply <span style="white-space:nowrap">INO-4800.</span> In certain instances, the Company will have the right to convert the exclusive license to a <span style="white-space:nowrap">non-exclusive</span> license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of <span style="white-space:nowrap">INO-4800</span> outside of the territories covered by the Restated Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Restated Agreement, the Company will continue to supply Advaccine&#8217;s clinical requirements of <span style="white-space:nowrap">INO-4800</span> and devices, although Advaccine may manufacture <span style="white-space:nowrap">INO-4800</span> for its clinical use and may procure alternate suppliers. Advaccine will continue to be responsible for the manufacture and supply of <span style="white-space:nowrap">INO-4800</span> itself or through a contract manufacturer for commercial use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that a global purchasing entity desires to enter into a purchase agreement for <span style="white-space:nowrap">INO-4800</span> in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply <span style="white-space:nowrap">INO-4800</span> to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Original Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million and a payment of $2.0&#160;million upon the dosing of the first subject in a Phase 2 clinical trial of <span style="white-space:nowrap">INO-4800</span> in China. Under the Restated Agreement, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of additional specified milestones related to the development, regulatory approval and commercialization of <span style="white-space:nowrap">INO-4800,</span> including the achievement of specified net sales thresholds for <span style="white-space:nowrap">INO-4800</span> in the expanded territory, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-licensed</span></span> product basis and <span style="white-space:nowrap"><span style="white-space:nowrap">region-by-region</span></span> basis, for ten (10)&#160;years after the first commercial sale in a particular region in the licensed territory or, if later, until the expiration of the <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> patent covering a given licensed product in a given region. Beginning in the first calendar year following the first commercial sale of <span style="white-space:nowrap">INO-4800</span> in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Restated Agreement will continue in force on a <span style="white-space:nowrap"><span style="white-space:nowrap">region-by-region</span></span> basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Restated Agreement (i)&#160;in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii)&#160;upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the Restated Agreement, upon prior written notice, if Advaccine (i)&#160;ceases all development or commercialization activities for at least 9 months, subject to certain exceptions, or (ii)&#160;challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Restated Agreement, subject to certain conditions. Advaccine may terminate the Restated Agreement at any time for convenience upon 9 months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of <span style="white-space:nowrap">INO-4800</span> in the licensed territory, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Restated Agreement is not complete and is qualified in its entirety by reference to the text of the Restated Agreement, a copy of which will be filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ending June&#160;30, 2021. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2021, the Company issued a press release announcing the Restated Agreement. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221;), and is not incorporated by reference into any of the Company&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br />No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d153894dex991.htm">Press Release, dated June&#160;8, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover page interactive data file (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">INOVIO PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: June&#160;11, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Peter Kies</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d153894dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of <FONT STYLE="white-space:nowrap">COVID-19</FONT> DNA Vaccine
Candidate, <FONT STYLE="white-space:nowrap">INO-4800</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phase 3 efficacy trial planned to commence this summer in areas of the world underserved
by vaccines </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">News follows recently announced Phase 2 data, which showed <FONT STYLE="white-space:nowrap">INO-4800</FONT> to be well-tolerated and
immunogenic in all age groups </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa.,&nbsp;June 8, 2021&nbsp;/PRNewswire/ &#151;&nbsp;INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely
designed DNA medicines to treat and protect people from infectious diseases, cancer, and <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases, today announced an expansion of its previously announced partnership with Advaccine
Biopharmaceuticals Suzhou Co., Ltd. (&#147;Advaccine&#148;) to jointly conduct a global Phase 3 segment of the ongoing Phase 2/3 trial called INNOVATE (<U><B>IN</B></U>OVIO I<B><U>NO</U></B>-4800<B>&nbsp;<U>V</U>a</B>ccine<B>&nbsp;<U>T</U></B>rial
for<B>&nbsp;<U>E</U></B>fficacy). Together, the companies will evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">INO-4800</FONT> in a <FONT STYLE="white-space:nowrap">two-dose</FONT> regimen (2.0 mg), administered one month apart,
in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-to-one</FONT></FONT> randomization in subjects 18 years and older across several countries, primarily in&nbsp;Latin America&nbsp;and&nbsp;Asia. The primary endpoint of the
Phase 3 segment will be virologically confirmed <FONT STYLE="white-space:nowrap">COVID-19</FONT> disease. The 2.0 mg dose was selected from the Phase 2 segment, where <FONT STYLE="white-space:nowrap">INO-4800</FONT> was shown to be generally
well-tolerated and immunogenic in all tested age groups. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J.&nbsp;Joseph Kim, President and CEO of INOVIO, said, &#147;With most countries in the
world currently registering COVID vaccination rates of less than 10%, INOVIO and Advaccine feel the urgency to advance <FONT STYLE="white-space:nowrap">INO-4800</FONT> into a global Phase 3 trial this summer. INOVIO is encouraged by our
recently&nbsp;published&nbsp;Phase 2 data for <FONT STYLE="white-space:nowrap">INO-4800,</FONT> which showed the vaccine to be well-tolerated and immunogenic in all tested age groups. In a&nbsp;previously announced study, <FONT
STYLE="white-space:nowrap">INO-4800</FONT> was also found to generate broad cross-reactive immune responses against tested <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants of concern, which may
enable it to provide greater protection for more people globally.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kim continued, &#147;We believe that <FONT STYLE="white-space:nowrap">INO-4800,</FONT> if approved,
will be well-positioned to serve the vaccine needs of the global community. Based on trial results to date, this vaccine has shown to be well-tolerated; produces balanced neutralizing antibodies and favorable T cell response (CD8 and CD4) and is
easy to administer. It is uniquely positioned to support vaccine rollout to underserved countries globally with a strong thermostability profile that is stable at room temperature for more than a year and does not require cold or ultra-cold-chain
transport. In addition to the potential approval as a primary vaccine, <FONT STYLE="white-space:nowrap">INO-4800</FONT> also has the potential to be used as a booster vaccine since the early clinical data supports that
<FONT STYLE="white-space:nowrap">INO-4800</FONT> can be safely <FONT STYLE="white-space:nowrap">re-administered.&#148;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founder and Chairman of
Advaccine, Dr.&nbsp;Bin Wang said, &#147;The&nbsp;expansion of our partnership with INOVIO has a lot of synergy and we are excited about the global Phase 3 trial of <FONT STYLE="white-space:nowrap">INO-4800.</FONT> We look forward to bringing a
well-tolerated and immunogenic <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine to more people around the world. Advaccine has built up large scale GMP manufacturing facilities of DNA vaccine and&nbsp;recently obtained the vaccine
manufacturing permit from Chinese regulatory authorities, becoming one of a few companies in&nbsp;China&nbsp;that have the license. We are working to expand our manufacturing capacities further, in order to meet the unmet global need for nucleic
acid-based <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under their expanded collaboration, INOVIO and Advaccine intend to share
equally, subject to specified limitations and conditions, the total cost of the planned global Phase 3 trial, which is estimated to be approximately&nbsp;$100&nbsp;million. The expanded partnership is an extension of an existing relationship between
the two companies, including an exclusive agreement&nbsp;announced&nbsp;in&nbsp;January 2021&nbsp;under which Advaccine has the exclusive rights to develop, manufacture and commercialize <FONT STYLE="white-space:nowrap">INO-4800</FONT>
within&nbsp;Greater China, inclusive of mainland&nbsp;China,&nbsp;Hong Kong,&nbsp;Macao&nbsp;and&nbsp;Taiwan. Under the expanded agreement, Advaccine obtains rights to additional Asian countries outside of&nbsp;Greater China. Advaccine has extensive
experience in <FONT STYLE="white-space:nowrap">co-development</FONT> of <FONT STYLE="white-space:nowrap">INO-4800</FONT> with INOVIO, including sponsoring both Phase 1 and Phase 2 clinical trials in&nbsp;China&nbsp;for
<FONT STYLE="white-space:nowrap">INO-4800.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global Phase 2/3 trial builds upon INOVIO&#146;s Phase 2 segment, which was funded by the U.S.
Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health
Agency. Results from the trial can be found in the paper entitled &#147;Safety and immunogenicity of <FONT STYLE="white-space:nowrap">INO-4800</FONT> DNA vaccine against
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2:</FONT></FONT> A Preliminary Report of a Randomized, Blinded, Placebo-controlled, Phase 2 Clinical Trial in Adults at High Risk of Viral Exposure,&#148; which has been
published as a <FONT STYLE="white-space:nowrap">pre-print</FONT> in MedRxiv prior to peer review.&nbsp;Early <FONT STYLE="white-space:nowrap">INO-4800</FONT> research and development funding were provided by the Coalition for Epidemic Preparedness
Innovations (CEPI) and the Bill&nbsp;&amp; Melinda Gates Foundation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the initiation of the clinical trial itself, INOVIO is in discussions
with several countries which are expected to provide clinical trial sites, regarding advanced market contracts to potentially supply <FONT STYLE="white-space:nowrap">INO-4800</FONT> upon respective regulatory approvals in those countries. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">INO-4800</FONT> &#147;INNOVATE&#148; Phase 2/3 Clinical Trial
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 segment of INNOVATE Phase 2/3 trial was designed to evaluate the safety, tolerability and immunogenicity of
<FONT STYLE="white-space:nowrap">INO-4800</FONT> in a <FONT STYLE="white-space:nowrap">two-dose</FONT> regimen (1.0 mg or 2.0 mg) in a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">three-to-one-randomization</FONT></FONT></FONT> to receive either <FONT STYLE="white-space:nowrap">INO-4800</FONT> or placebo in three age groups <FONT
STYLE="white-space:nowrap">(18-50</FONT> years, <FONT STYLE="white-space:nowrap">51-64</FONT> years and 65 years and older). The Phase 2 data showed that <FONT STYLE="white-space:nowrap">INO-4800</FONT> was well-tolerated and immunogenic in all
tested age groups, and the 2.0 mg dose was selected to advance into the Phase 3 segment of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global Phase 3 segment of the trial intends to
enroll healthy men and <FONT STYLE="white-space:nowrap">non-pregnant</FONT> women 18 years of age and older, to evaluate the efficacy of <FONT STYLE="white-space:nowrap">INO-4800</FONT> (2.0 mg) in a <FONT STYLE="white-space:nowrap">two-dose</FONT>
regimen based on the Phase 2 dose-confirmation data. The trial will be predominantly conducted in vaccine underserved countries in&nbsp;Latin America&nbsp;and&nbsp;Asia. Participants will be enrolled in a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">two-to-one</FONT></FONT> randomization to receive either <FONT STYLE="white-space:nowrap">INO-4800</FONT> or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the
incidence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> during the Phase 3 segment. The primary endpoint of the Phase 3 segment will be virologically confirmed <FONT STYLE="white-space:nowrap">COVID-19</FONT> disease.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INO-4800</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">INO-4800</FONT> is INOVIO&#146;s DNA vaccine candidate against <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the novel coronavirus that causes
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> INOVIO has extensive experience working with coronaviruses and was the first company to initiate a Phase 2a trial for <FONT STYLE="white-space:nowrap">INO-4700,</FONT> a DNA vaccine candidate for a
related coronavirus that causes Middle East Respiratory Syndrome (MERS). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Composed of a precisely designed DNA plasmid,
<FONT STYLE="white-space:nowrap">INO-4800</FONT> is injected intradermally followed by electroporation using a proprietary smart device delivering the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune
response. <FONT STYLE="white-space:nowrap">INO-4800</FONT> is the only nucleic-acid based vaccine that is stable at room temperature for more than a year, at 37<SUP STYLE="font-size:85%; vertical-align:top">o</SUP>&nbsp;C for more than a month, has
a five-year projected shelf life at normal refrigeration temperature and does not need to be frozen during transport or storage &#150; all of which are important considerations when preparing for mass immunizations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO&#146;s DNA Medicines Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO has 15
DNA medicine clinical programs currently in development and focused on <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and
<FONT STYLE="white-space:nowrap">COVID-19</FONT> that are being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of precisely designed&nbsp;DNA
plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally
using INOVIO&#146;s proprietary hand-held smart device called CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. The CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;device uses a brief electrical pulse to
reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen
is processed naturally in the cell and triggers the desired T cell and antibody mediated immune responses. Administration with the CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;device ensures that the DNA medicine is
efficiently delivered directly into the body&#146;s cells, where it can go to work to drive an immune response. INOVIO&#146;s DNA medicines do not interfere with or change in any way an individual&#146;s own DNA. The advantages of INOVIO&#146;s DNA
medicine platform are the relative speed at which DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, and tolerability that have been
observed in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With more than 3,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range
of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with the potential to meet urgent global health needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a biotechnology company focused
on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine
can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO&#146;s lead candidate <FONT STYLE="white-space:nowrap">VGX-3100</FONT> is the first DNA medicine
to achieve efficacy endpoints in a Phase 3 clinical trial, REVEAL 1, for the treatment of precancerous cervical dysplasia caused by <FONT STYLE="white-space:nowrap">HPV-16</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-18.</FONT> <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> also demonstrated positive Phase 2 efficacy results in separate trials evaluating the treatment of precancerous vulvar dysplasia and anal dysplasia. Also in development are programs targeting <FONT
STYLE="white-space:nowrap">HPV-related</FONT> cancers and a rare <FONT STYLE="white-space:nowrap">HPV-related</FONT> disease, recurrent respiratory papillomatosis (RRP);
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-HPV-related</FONT></FONT> cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika,
Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill&nbsp;&amp; Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV
Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific,&nbsp;University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards &#147;W&#148; designation recognizing companies with more than 20% women on their board of directors. For more information,
visit&nbsp;www.inovio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media:&nbsp;Jeff Richardson,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,&nbsp;jrichardson@inovio.com</FONT></FONT><U></U><U>&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors:&nbsp;Ben Matone, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,&nbsp;ben.matone@inovio.com</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical
studies and clinical trials and the availability and timing of data from those studies and trials, and our ability to successfully manufacture and produce large quantities of our product candidates if they receive regulatory approval. Actual events
or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials, product development programs and
commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for
products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted
by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they
or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of
invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or
collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended&nbsp;December 31, 2020, our Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended&nbsp;March 31, 2021&nbsp;and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate
in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided
herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ino-20210607.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-8 Build:20210114.4 -->
<!-- Creation date: 6/11/2021 11:42:00 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:ino="http://www.inovio.com/20210607"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.inovio.com/20210607"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210607_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210607_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ino-20210607_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-8 Build:20210114.4 -->
<!-- Creation date: 6/11/2021 11:42:00 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ino-20210607_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-8 Build:20210114.4 -->
<!-- Creation date: 6/11/2021 11:42:00 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ino-20210607.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>d153894d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20210607.xsd" xlink:type="simple"/>
    <context id="duration_2021-06-07_to_2021-06-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-06-07_to_2021-06-07">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-06-07_to_2021-06-07"
      id="Hidden_dei_EntityCentralIndexKey">0001055726</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-06-07_to_2021-06-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-06-07_to_2021-06-07">2021-06-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-06-07_to_2021-06-07">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-06-07_to_2021-06-07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-06-07_to_2021-06-07">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-06-07_to_2021-06-07">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-06-07_to_2021-06-07">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-06-07_to_2021-06-07">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-06-07_to_2021-06-07">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-06-07_to_2021-06-07">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-06-07_to_2021-06-07">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-06-07_to_2021-06-07">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-06-07_to_2021-06-07">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-06-07_to_2021-06-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-06-07_to_2021-06-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-06-07_to_2021-06-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-06-07_to_2021-06-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-06-07_to_2021-06-07">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-06-07_to_2021-06-07">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-06-07_to_2021-06-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-06-07_to_2021-06-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140005858307448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  07,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ +X#+4I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    "  O@,M2NF66 .T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  O@,M2F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "^ RU*U8=3:5@0  .L0   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  O@,M2GZ ;\+$"  #B#
M#0              @ &8#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "^
MRU*7BKL<P    !,"   +              "  70/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( "^ RU(<.&7J/P$  #P"   /              "  5T0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  O@,M2)!Z;HJT   #X 0  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  O@,M299!YDAD!  #/ P  $P              @ &N$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #X$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d153894d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d153894d8k.htm">d153894d8k.htm</File>
    <File>d153894dex991.htm</File>
    <File>ino-20210607.xsd</File>
    <File>ino-20210607_lab.xml</File>
    <File>ino-20210607_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d153894d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d153894d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20210607_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20210607_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20210607.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20210607",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d153894d8k.htm",
      "contextRef": "duration_2021-06-07_to_2021-06-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d153894d8k.htm",
      "contextRef": "duration_2021-06-07_to_2021-06-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com//20210607/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-21-188845-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-188845-xbrl.zip
M4$L#!!0    ( "^ RU)YR()8@!<  'R'   .    9#$U,S@Y-&0X:RYH=&WM
M/6U3(S?2WZ_J_H/*2:[8*K^->5DPNUP1PR;<[@('Y))ZOJ3D&1DK.YZ92#.
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MCX5=N2X)OQ:-OA+\"Z8\(:CO\IL8.&1IQ'E$NO*\K,!-K,1.76(D-K46X F
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M[6F7KJZ%R6H/MR?]7F^.FEF#VQ]02P,$%     @ +X#+4I*FVC2"!@  2D<
M !0   !I;F\M,C R,3 V,#=?;&%B+GAM;,V<;V_;-A#&WP_H=[AY;S:@LBVW
M&%:C:9$YR1 L;8+&W88-0R%+C$U,)@U2CNUO/U)_&CFF9"HZ5GG15I'NGKM'
M^9W*2'+>OM\N8[@G0E+.3GI^?]@#PD(>438_Z:VE%\B0TA[()&!1$'-&3GH[
M(GOOW[WX[NWWG@=G%Y<?P8-%DJSD>##8;#;]Z(XRR>-UHB1E/^3+ 7A>$3^9
M?H8_LG)C^$1B$D@"H^%HZ/T"OZYI'(W5%_[0]U_W7Y?3! FT'D1!0L;P\\#W
M!SH0?'_\>C0>#N'F YP',B&"P90N23F7KW:"SA<)_!C^!&G6&6>,Q#'9P05E
M 0MI$,-MT?)+N&1A'T[C&#[I-*GZE$3<DZB?J\:4_3?6?\UT]_#B.P!U&IE,
M]YWT],G(S\5V)N(^%W/5[/#5H$CI/61L#U(VK]($_\V;-X/T:#E:4E.L$O<'
M?WVXN@T79!EXZO2K;U>8EY%T+-/]5SQ,SZ%%@U 9H;_RBC!/[_+\D??*[V]E
MU'NG"^9G)YB1^$IM0>IA+'A,:@KKPVGU7AZ?[%8JGFP3PB*2*W_5YF$>M1#D
M+E/5\*62DH3].;\?1(1J0H9ZPTL!&_IYGS^H75\F7%%_.I.)",)DOVJL3Q07
MQ<[4RDG/D#38;TO'G8IP3RL08:&C-H^<A3QB$'+UW5LE7JI8I-\)OC1VD9?C
MAH-?XEEL;%/SI+;TD!/F?;X]YC43*AL31/*U4) U^0:G?MZERO!/H?WOV\%#
M[>?2JKJ02'+5M%\,,$^7"GGU)[F(@[DMF(^2.@+3W#HW'&P#ID$("<RORJ"E
M6V/IH-$REK;=8D!YSA*:[":JF CB2W5)WOY.=K9P5B1W!&F]%5X3U ;:&D$D
M>+,*D)> M :H(JTQ=MAZ&>?F_6. ?<;#M9ZAJ?)@R_-^3D<8&QOGA\?:0'NH
M@\1J(0Q:N36@^&V6N;3L%1/&&R(HC\Y9=*9^VFE*Y:/DCO$T6^$U01C &@2Q
MR<U*@*H!N@@:Q Y:-])LW3_>\N$3F5.]A&;)QV!IS;4YM]/%0X417AW3?NE@
MTL-=.3Q4 %T":=W@HF_#LL&Z>3R<+UG(Q8J+]*;*;:*&:,+7:O&RF_"H(=U'
MI#J%W<XFMTYI/PH6\KB3L5<0THJ0EP1=$VE4OH$OP^0\W1S>*%W0F'Q<+V=$
M-)N;<EZG0V(PP,W'V^/_6 N7=:T.F3P2UMC]&ABV:AH/UVFPO8S4(HK>T>R6
M^E/8K13I%.1CUKA%<'O$:X5Q>5>E8+\6+OU.K1A&X0E^\ ;C-(J4#9G_<T49
M\9L-A5&@TX&HL\2/!+8?A$I1W"'(]5\6&Z KP37#6MDXLV$8@"=X<3D H[8#
M,'IV S"R'8"1BP$8?;L!F&ZXLP% LF$] +5>T =@HC:OQ91OV)/P+Z<_!_@-
M=DSH/X2A@?]8TA'VN@QP ;H0+O+8!NJ MW.!#GOZ,_.UN!'\GK*PX:V?*HWG
M@'V5,1/[CV+1!L"HZV@*LIL?"J"B&NXH.+%2-P\-_* /Q0V721#_35?-[X::
M%9[#0)A-F<9A+Q)M& RJCD8AJP2J%.8=3G<VZL; V@O*>X7:IB!!$^SW<[IZ
MJ]#4.#\\UNJ=P@,=)'S3__FU,@ZM^'WNO4]HV2P&COJEW_AFP5G#^^N'>1UA
M66F FX^WP=.LA81H*@ZI.M8=1C?]EE%MTC0&KG\*FB2$3?ARN6;Y_4MIRVQ%
M<D?@UEOA-4%M$*X11.(XKP#[)5JS[+#Q,M!-N\> ^I;'-*0)9?,/:CTN:!#;
M$FW*[ CG&A.\*J(-R%5J2!0_R$.AWQIA5RV7^6W4-P:\-X+H62$*CO0=2_UY
M''%]=V>_E*A3Z AF"U/\6&0;N(^I(D&NRD"Y#F2%(*W4&G?7)LK8/]&)@P&X
ME')-1/LQ,.@\CV&H-F@>B8-XQ,&HT'8U'EDYIU/BR%'MK#2RA;+@(>%:K;-V
M_F@VI4EL?1_D,*^KQ4Z5 6X^WFJA8]3"6N;DXJ#4(95OO\IQTN_>&J=!TQBX
M3D6@/^]^NUO.N/72_%%21Z":6^>&@VT0-0@A\9DK0R;=FDT'C9;!M.T6\QIZ
MO@T7RC-I\I$)<V['UU*C$5X=@W%-/=3#OJX6%7 ^,N&N;^/UU;)YO&>#YTLB
MYFJ"?A-\DRS4(F45L(8?(ZZ0Z/3I8+TM?C2T_?/!&EDDXO.':D4AR"I!7@KI
M^:!#&X8'A+9>RCNNU);^%3#Y+IK](A2UYW]02P,$%     @ +X#+4MT[A@;&
M!   RRP  !0   !I;F\M,C R,3 V,#=?<')E+GAM;-V:78_B-A2&[U?:_^!F
M;UJI(0DS.[N#AEU19J9"G0\$;%OU9F62 UAU;&2' ?Y]CT/<$@BS,-NMXG+!
MA^/W^/5Y'!,[N?JX2CEY J69%&TO:H0> 1'+A(EIVUMHG^J8,8_HC(J$<BF@
M[:U!>Q\_O'YU]9WOD^O;W@/QR2S+YKH5!,OELI%,F-"2+S(,J1NQ3 /B^[9^
M=_2)_+IIKD4&P(%J(,VP&?KOR4\+QI,6_HC"*#IOG&_+%% 3CR0T@Q:Y"*(H
M,!5)%+7.FZTP)/U[<D-U!DJ0$4MA6ROG:\6FLXQ\'_] <M6U% (XAS6Y98**
MF%%.AM;RCZ0GX@;I<$X&1J;1IP;U!$FCB,J9^+-EWL;&/7G]BN +$RET7MKV
M3#J*;*S&BC>DFJ+=\"RP(F];L]H3+<]R271Y>1GD1\OU-:NJC0U$P>_W=\-X
M!BGU$0)"BW>:0C=)]K=ZV]S;8'/0UM>LI?-(=S+.<W]$M\C!&N:7;ZOYILB/
MFOY9U%CIQ/M@FMQD54D. Y@0\_EIT"NUR81\8C(?43G\\")\%V1T)85,UX%1
M!-<R7J0@,OO9$<F-R%BV[HF)5&G>#X_D*6W-%$S:'@;U;3!CYLT XWP^)4ZV
MGN-9H5DZY^"18*LS<X4#1V1Y[3LL* E@E8%((+%AC/]OTMT/&Z#%J)5QJ?OV
MQ,UI:8@;4_D4),!,BZ'YXN<G9Q@5K-Y@T>>NQ!FC,]:9HG%63@,W@T4J6\CI
M&'C;JQ %_[ZM#J8@,6FXY71ZK*T=4=G6-L".BDLAJ8IM./RZ1Z\\_(L:P9PJ
MC.?',YSIK'JB9%J9HJ(U66E4J@14VVLV&WC:>V2NF%0('DL\LM#H1<Z-:\K-
M,9B 4I#<;;I]T&5N$:=0#7G-;P)I,SZ[V ]%>0]/@-4OL#X6U@%Q?:$=,&SA
MG3D&S\XS(TSFL<S*FOJB*ONTA-XZ2J@/Z!C_#))KO& Z%=6.N/[,=@Q;>!>.
MP=O,%@.8,M-=D3W0]&AVU=KZHJOV:\F]<Y(<KANDFDN5)WB(>8:N7.#4O^[*
MY$207PA5=ZY?L&\QOW<2\RWC\+!(QZ!.8[JMJSO ;:^6UJ63M$9TU4LP&6S"
M-NO8EZ [&*3N' \:+Z">A4Y"[20)IEH7'[BVAN@TH)4!Z@ZSTK0%&?U/0#:_
M%F3319#-?T"ZN:(O^M+%KX]J))?B11BWY8Y W+9L$;JVKB]U*+]<>U1])9^8
MV3]^"<>]&([ W/-MB9Z[3+0O=4;Y'VQ^^CJD.H(C-'=<6Y:N[>F8&::C@)Y"
MKZRI+Z^R3TO(M8T;<XN,]V=2G+@NW-?5E]2^5TO+M<V:W]!E!J(KTW0ABF61
M/A;9 7%]N1TP;.&YM@4SE)S%+&-B>H]_U8H9@\>1JU+6%UN56\O,M8V8O@(S
M_ "OJ/([+.:^MWJ<3(Z?*)^+4%^&S[DN6)Z[MO^RTZ>>U@M07T^T(HXS7"N\
M6[JN;<H,(5X8HU%S/&(9/_IR<U]77WK[7BTMUW9>1HJ:!_6&ZW0LC_X;W!'5
ME]..40O)M;T5.]QN5O&,BBF<<E.W6EM?9-5^+3DW]U!N4E!3'(<_*[G,9CCO
MSZDX\8&E R'JR_%9VQ;G?["-<A7LI>8."\PSN)LCYLT\48HE?P%02P$"% ,4
M    "  O@,M2><B"6( 7  !\AP  #@              @ $     9#$U,S@Y
M-&0X:RYH=&U02P$"% ,4    "  O@,M2=&"LE_L:  #:6@  $0
M    @ &L%P  9#$U,S@Y-&1E>#DY,2YH=&U02P$"% ,4    "  O@,M27OJA
MKV$#   >#   $               @ '6,@  :6YO+3(P,C$P-C W+GAS9%!+
M 0(4 Q0    ( "^ RU*2IMHT@@8  $I'   4              "  64V  !I
M;F\M,C R,3 V,#=?;&%B+GAM;%!+ 0(4 Q0    ( "^ RU+=.X8&Q@0  ,LL
M   4              "  1D]  !I;F\M,C R,3 V,#=?<')E+GAM;%!+!08
1    !0 % #T!   10@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
